Skip to main content
. Author manuscript; available in PMC: 2017 Feb 6.
Published in final edited form as: Semin Immunol. 2016 Feb 6;28(1):73–80. doi: 10.1016/j.smim.2016.01.001

Table 4.

Clinical trials involving the combination with epigenetic modulators and immunotherapy.

Immune Checkpoint blockade + Epigenetic modulator
Clinical trial Condition Phase Intervention
NCT02395627 Breast Phase II Pembrolizumab+Tamoxifen+Vorinostat
NCT02538510 Head&neck Phase I/II Pembrolizumab+Vorinostat
NCT02437136 NSCLC/Melanoma Phase I/II Pembrolizumab+Entinostat
NCT01928576 NSCLC Phase II Azacitidine –> Nivolumab
Azacitidine+Entinostat –> Nivolumab

NSCLC = non-small cell lung cancer;